Form 4 for DYN Dyne Therapeutics, Inc.
Accepted 2026-02-17 00:00:00 ET · period of report 2026-02-12 · accession 0001193125-26-055075 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-17 | 2026-02-12 | DYN | Cox John | CEO, Pres, Dir | A - Grant | $0.00 | +180.0K | 376.9K | +91% | $0 |
| D | 2026-02-17 | 2026-02-12 | DYN | Cox John | CEO, Pres, Dir | A - Grant | $0.00 | +285.0K | 285.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-12 | A | A | 180,000 | $0.00 | 376,877 | D | — | — | (F1) Consists of shares of Common Stock issuable under 180,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026. (F2) Includes 288,976 unvested RSUs. |
| 2 | Derivative | Stock option (right to buy) | 2026-02-12 | A | A | 285,000 | $0.00 | 285,000 | D | $16.00 · — to 2036-02-11 | 285,000 Common Stock | (F4) This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030. |